The active form of vitamin D 3 , 1α,25-dihydroxyvitamin D 3 [1α,25(OH) 2 D 3 ], functions to maintain calcium and phosphorus homeostasis and plays an important role in cell proliferation and differentiation. Since the discovery of non-classical functions of 1α,25(OH) 2 D 3 , many 1α,25(OH) 2 D 3 analogs have been synthesized to separate calcemic properties from the antiproliferative cell-differentiating properties. 1α,25(OH) 2 D 3 and its precursor, 25-hydroxyvitamin D 3 [25(OH)D 3 ], are metabolized via C-24 and C-23/26 oxidation pathways. Recently, a novel A-ring modification metabolic pathway of 1α,25(OH) 2 D 3 , the C-3 epimerization pathway, was identified. In our laboratory, C-3 epimerized metabolites of major natural vitamin D 3 metabolites, 1α,25(OH) 2 D 3 , 25(OH)D 3 and 24,25-dihydroxyvitamin D 3 [24,25(OH) 2 D 3 ], and a synthetic analog, 22-oxacalcitriol [22-oxa-1α,25(OH) 2 D 3 , OCT], were identified. In addition, other novel metabolites of OCT were assigned to two kinds of C-25 dehydrates, 25-dehydroxy-25-ene-22-oxa-1αhydroxyvitamin D 3 [25-ene-22-oxa-1α(OH)D 3 ] and 25-dehydroxy-24-ene-22-oxa-1α-hydroxyvitamin D 3 [24-ene-22-oxa-1α(OH)D 3 ]. In this mini-review, the identification of C-3 epimers of vitamin D 3 compounds and C-25 dehydrates of OCT using 1 H-NMR and LC-MS techniques is described. Furthermore, the cell-specific generation and biological activity of these novel metabolites are reviewed.
INTRODUCTION
Vitamin D 3 is obtained from the diet and synthesized in the skin from the precursor 7-dehydrocholesterol by exposure to sunlight. Vitamin D 3 is metabolized to 25-hydroxyvitamin D 3 [25(OH) D 3 ] in the liver and subsequently to the active form of vitamin D 3 , 1α,25-dihydroxyvitamin D 3 [1α,25(OH) 2 D 3 ], or the inactive form of vitamin D 3 , 24,25-dihydroxyvitamin D 3 [24, 25(OH) 2 D 3 ], in the kidney. 1α,25(OH) 2 D 3 plays an essential role in calcium homeostasis, 1) cell proliferation and differentiation. [2] [3] [4] 1α,25(OH) 2 D 3 exerts its functions through the steroid hormone receptor family. 5) It is evident that a variety of cells and tissues not primarily related to calcium or bone metabolism also contain the vitamin D receptor (VDR). 6) The widespread distribution of the VDR in target cells indicates that 1α,25(OH) 2 D 3 is an important modulator of proliferation and differentiation in normal and malignant cells. 25(OH)D 3 and 1α,25(OH) 2 D 3 are further metabolized via C-24 or C-23/26 oxidation pathways by 25-hydroxyvitamin D 3 24 -hydroxylase (24OHase, CYP24). 7, 8) The C-24 oxidation pathway, initiated by C-24 hydroxylation, yields C-24 oxo compounds and ultimately results in the formation of side-chain cleavage products. 9, 10) The C-23/26 oxidation pathway, initiated by C-23 or C-26 hydroxylation, results in the production of metabolites with a lactone-ring in the side-chain. 11, 12) Recently, a novel A-ring modification metabolic pathway of 1α,25(OH) 2 D 3 was identified in human colon *To whom correspondence should be addressed: Department of Hygienic Sciences, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan. Tel.: +81-78-441-7563; Fax: +81-78-441-7565; E-mail: t-okano @kobepharma-u.ac.jp adenocartinoma cells, 13) rat osteosarcoma 14) and various cell lines, 15) which is initiated by epimerization of the hydroxyl group at C-3, the C-3 epimerization pathway. The C-3 epimerization results from a change in the orientation of the hydroxyl group at the C-3 position from the β to the α. 3-Epi-1α,25(OH) 2 D 3 was also identified as a circulating metabolite of 1α,25(OH) 2 D 3 in rats treated with pharmacological doses of 1α,25(OH) 2 D 3 . 16) It was indicated that the C-3 epimerization pathway is target cell-specific 14, 15) and cell differentiation-related. 13) However, little is known about the biological functions of this metabolic pathway. We performed experiments to characterize the C-3 epimerization of natural vitamin D 3 metabolites, 25(OH)D 3 and 24,25(OH) 2 D 3 , 17) as well as 1α,25(OH) 2 D 3 . We also examined the C-3 epimerization of a 1α,25(OH) 2 D 3 analog, 22-oxacalcitriol [22-oxa-1α,25(OH) 2 D 3 , OCT], containing an oxygen atom at position 22 and identified another novel metabolic pathway, the C-25 dehydration pathway. 18) Furthermore, the production of the C-3 epimer and C-25 dehydrates in various cell lines and the biological activities of the novel metabolites were tested.
Identification of Novel Metabolites of Vitamin D 3 Compounds
After incubation of 10 µM of 1α,25(OH) 2 D 3 with rat osteosarcoma-derived UMR-106 cells for 48 hr, lipid extracts from the media along with the cells were applied to a HPLC system using a silica gel column. The metabolite corresponding to an authentic standard of 3-epi-1α,25(OH) 2 D 3 was observed as well as metabolites from the C-24 oxidation pathway and assigned to 3-epi-1α,25(OH) 2 D 3 by 1 H-NMR and GC-MS analyses. 15) In addition, lipid extracts from the media and cells incubated with 10 µM of 25(OH)D 3 for 48 hr were applied to two kinds of HPLC systems using a silica gel column or a chiral column for the separation of 3-epi-25(OH)D 3 from 25(OH)D 3 . The metabolite corresponding to an authentic standard of 3-epi-25(OH)D 3 was purified for structure assignments by 1 We also examined the metabolism of a 1α,25(OH) 2 D 3 analog, OCT. OCT has received government approval for use as an agent for the treatment of secondary hyperparathyroidism and psoriasis in Japan. Incubation of 10 µM of OCT with UMR-106 cells for 48 hr resulted in the formation of five metabolites. Two of the five were polar metabolites of OCT and identical to the previously identified 1α,20-dihydroxyvitamin D 3 [1α,20(OH) 2 D 3 ] and 24hydroxy-OCT [24(OH)OCT]. The other three metabolites were less polar than substrate OCT and have not been identified to date. The retention times of HPLC, 1 H-NMR and LC-MS spectra of one of three less polar metabolites were completely congruent with those of authentic 3-epi-OCT and this metabolite was identified as 3-epi-OCT. 18) Reddy et al. 21) also demonstrated that synthetic vitamin D analogs, 1α,25(OH) 2 -16-ene-23-yne-vitamin D 3 and 1α, 25(OH) 2 -16-ene-23-yne-20-epi-vitamin D 3 , are metabolized to their respective C-3 epimers in UMR-106 cells. Two other less polar metabolites of OCT were predicted to have OCT-like structure with an additional exo-methylene group at the end of the side-chain and an olefin group introduced between C-24 and C-25 as a result of dehydration at the C-25 hydroxyl group of OCT from the findings of 1 H-NMR. 18) In the LC-MS spectra of these less polar metabolites, [M+NH 4 ] + was observed at m/z 418. . We also observed the two C-3 epimers of the C-25 dehydrates, 25-ene-3epi-22-oxa-1α(OH)D 3 and 24-ene-3-epi-22-oxa-1α(OH)D 3 , as metabolites of 3-epi-OCT. These results suggest that C-3 epimerization of the A-ring is a common metabolic pathway for the major metabolites of vitamin D 3 and synthetic analogs (Fig. 1) . In addition, we demonstrated for the first time that OCT was metabolized via the C-25 dehydration pathway. The less polar metabolites of 1α,25(OH) 2 D 3 corresponding to dehydrates of 1α,25(OH) 2 D 3 were observed in UMR-106 and ROS 17/2.8 cells. However, definite structure assignments of the dehydrated metabolites of 1α,25(OH) 2 D 3 have not been completed.
Cell-Specific Generation of Novel Metabolites
When metabolism of 25(OH)D 3 in five kinds of cell culture systems was examined, 3-epi-25(OH)D 3 and 24,25(OH) 2 D 3 were formed in all cell lines (Fig. 2) . In cell cultures of UMR-106 (rat, osteosarcoma), MG-63 (human, osteosarcoma), Caco-2 (human, colon adenocarcinoma) and Hep G2 (human, hepatoblastoma), 3-epi-25(OH)D 3 was predominantly generated, whereas 24,25(OH) 2 D 3 was the major metabolite in LLC-PK 1 cells (porcine, kidney). In Hep G2 cells, which generated 3-epi-25(OH)D 3 most abundantly among the cells, the amount of 3epi-25(OH)D 3 was approximately 8-fold grater than that of 24,25(OH) 2 D 3 . This finding suggests that vitamin D 3 is metabolized to 25(OH)D 3 and subsequently metabolized to 3-epi-25(OH)D 3 in the liver. In contrast, the kidney may work in the metabolism of vitamin D compounds via the C-24 oxidation pathway rather than the C-3 epimerization pathway.
The production rates of OCT metabolites in UMR-106, Caco-2 and LLC-PK 1 cells were also examined. 25-Ene-22-oxa-1α(OH)D 3 , 24-ene-22oxa-1α(OH)D 3 and 3-epi-OCT were generated in all cell lines tested, although there were differences in the amounts of products formed among the cell types ( Fig. 3 ). 18) The major metabolite found in the cell cultures of Caco-2 and LLC-PK 1 was 24(OH)OCT, whereas 25-ene-22-oxa-1α(OH)D 3 appeared to be more prevalent in UMR-106 cells. Interestingly, in UMR-106 cells the production ratio of 25-ene-22oxa-1α(OH)D 3 to 24-ene-22-oxa-1α(OH)D 3 was 2 : 1, however in Caco-2 and LLC-PK 1 cells, the production ratios of 25-ene-22-oxa-1α(OH)D 3 to 24ene-22-oxa-1α(OH)D 3 were 1 : 4 and 1 : 11, respec-tively. Therefore, the C-25 dehydration process of OCT appears to be under strict cell-specific control, or further metabolism of the dehydrates may differ with cell line.
Biological Activity of the Novel Metabolites
VDR and vitamin D binding protein (DBP) binding affinity, transcriptional activity and anti-proliferative and differentiation-inducing activity of 1α,25(OH) 2 D 3 , 25(OH)D 3 , 24,25(OH) 2 D 3 and their C-3 epimers are shown in Table 1 . 15, 17) The results indicate that the VDR binding affinities of C-3 epimers are lower than those of 1α,25(OH) 2 22) and in inhibiting keratinocyte proliferation, 23) and more potent than 1α,25(OH) 2 D 3 in inducing HL-60 cell apoptosis. [24] [25] [26] In addition, a high metabolic stability of 3-epi-1α,25(OH) 2 D 3 in target cells has been proposed by Reddy et al. 27) Thus, the C-3 epimerization pathway appears to play an important role not only in the regulation of intracellular concentrations of 1α,25(OH) 2 D 3 and its analogs, but also in the formation of metabolite(s) with a different biological activity profile. The biological activities of OCT and its less polar metabolites are shown in Table 2 . 18 the transcription-inducing activities on a rat 24OHase gene promoter in transfected MG-63 cells were about 2, 11 and 15% of OCT for 25-ene-22-oxa-1α(OH)D 3 , 24-ene-22-oxa-1α(OH)D 3 and 3-epi-OCT, respectively. Thus, 24-ene-22-oxa-1α(OH)D 3 and 3-epi-OCT were found to be less active than OCT, with potencies between 1/3 and 1/10 in terms of the activation of vitamin D-target genes. At 10 -8 M, no metabolites of OCT showed significant activity in arresting the cell cycle at the G0-G1 phase compared to 1α,25(OH) 2 D 3 and OCT. Three OCT metabolites had little inducing effect on cell surface CD11b antigen expression in a human promyelocytic leukemia cell line, HL-60. The findings of the biological studies here with two dehydrates of OCT demonstrated that their biological activities are considerably lower than OCT. Thus, it appears that like the C-23/C-24 hydroxylation pathways, the C-25 dehydration pathway contributes to reducing the high potency of OCT.
In summary, we demonstrated that both natural vitamin D 3 metabolites [25(OH)D 3 , 1α,25(OH) 2 D 3 and 24,25(OH) 2 D 3 ] and a synthetic 1α,25(OH) 2 D 3 analog (OCT) were metabolized via the C-3 epimerization pathway. Furthermore, we also demonstrated that OCT is metabolized to two kinds of dehydrates via the C-25 dehydration pathway. The interplay of these metabolic pathways may be important in the regulation of vitamin D metabolism and its biological activity. To understand the biological function of these novel metabolic pathways of vitamin D, identification of the enzymes responsible for C-3 epimerization and C-25 dehydration will be required. a) The values represent the relative binding affinity to OCT (expressed as 100), calculated from the concentration of each compound needed to achieve 50% displacement of [ 3 H]-1α,25(OH) 2 D 3 from VDR or DBP. b) The values are expressed as percentage activity at 10 −8 M in comparison with OCT (expressed as 100% activity).
